GSK gives Q2 results, revises outlook

6 days ago 2

GSK press release (NYSE:GSK): Q2 Non-GAAP EPS of 46.50p
Revenue of £7.99B (+1.1% Y/Y)
Specialty Medicines sales £3.3 billion (+15%); Respiratory, Immunology & Inflammation £1.0 billion (+10%); Oncology £0.5 billion (+42%); HIV sales £1.9 billion (+12%)
Vaccines sales £2.1 billion (+9%); Shingrix £0.9 billion (+6%); Meningitis

Recommended For You